Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 3:50 AM ET

Sponsor Check › Person

Bob Rappaport

Named as an officer, director or promoter on SEC Form D filings · CA, OH · Dec 22, 2017 → Mar 25, 2019

1deal (issuers)

$2.23Mreported sold

30investors

5Form D filings

2017–2019years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:40 AM ET · SEC enforcement last checked: not yet

The short version

Bob Rappaport is listed as a director on 5 SEC Form D filings by 1 issuer between Dec 2017 and Oct 2022: Elysium Therapeutics, Inc. (Akron, OH — biotechnology — 2017–2022; $2.23M reported sold to 30 investors).

What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.

Listed alongside Alex Gregory Sturmer (5 shared filings), Kathy LaPorte (5 shared filings), Thomas E. Jenkins (5 shared filings), Carey Ng (2 shared filings) and James Hackworth (2 shared filings).

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Bob. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), state securities regulators (AZ, CA, DE, TX, WA) — none found. Not yet searched: SEC enforcement releases.

What this means Nothing turned up where we looked (2 sources). That does not prove there is nothing — it means none was found in those sources on that date.

What the community is saying

Nothing found on Reddit, BiggerPockets or community forums for high-net-worth investors (searched Oct 24, 2026) — search queued; this line updates when it has run.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:40 AM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

Not yet searched

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

No SEC search has run yet for this person.

3. Bankruptcies

None found in sources searched

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:40 AM ET.

4. Differences between public sources

Not made for individual people — comparisons cover issuers and sponsor groups

5. Money to insiders

0 of 4 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $40,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Oct 11, 2022 D/A Elysium Therapeutics, Inc. File 021-380638	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 25, 2019 D Elysium Therapeutics, Inc. File 021-335538	$0	$0	$0	None listed on this filing	EDGAR ↗
Sep 20, 2018 D Elysium Therapeutics, Inc. File 021-321821	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 22, 2017 D Elysium Therapeutics, Inc. File 021-301555	$0	$0	$40,000 (est.) Wages to CEO.	None listed on this filing	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 1

Every issuer that named Bob Rappaport on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Biotechnology

Elysium Therapeutics, Inc.

Akron, OH · Dec 22, 2017 → Oct 11, 2022 · 5 filings

Oct 11, 2022 · D/A · $2,226,000 sold of $9,132,478 · 30 investors · min. No minimum reported · role: Director EDGAR ↗
Nov 16, 2020 · D · $915,000 sold of $1,000,000 · 23 investors · min. $1 · role: Director EDGAR ↗
Mar 25, 2019 · D · $214,992 sold of $1,499,999 · 4 investors · min. $1 · role: Director EDGAR ↗
Sep 20, 2018 · D · $931,985 sold of $2,328,829 · 21 investors · min. $1 · role: Director EDGAR ↗
Dec 22, 2017 · D · $651,778 sold of $1,500,000 · 14 investors · min. $1 · role: Director EDGAR ↗

Raised $2.23M from 30 investors (24% of the $9.13M target) as of the latest filing. Bob is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

People around Bob 5

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

Person